Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study

Antibodies to watch in 2021

(2021) Hélène Kaplon et al.   mAbs

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

(2020) Imtiaz A Samjoo et al.   Journal of Comparative Effectiveness Research

Evaluation of the Ability of Immune Humanized Mice to Demonstrate CD20-Specific Cytotoxicity Induced by Ofatumumab

(2019) Kenrick M. Semple et al.   CTS-Clinical and Translational Science

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies

(2019) Lori Mayer et al.   Multiple Sclerosis and Related Disorders

Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes

(2019) Laura Kähäri et al.   JOURNAL OF CLINICAL INVESTIGATION

Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys

(2019) Diethilde Theil et al.   Frontiers in Immunology

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

(2018) Raju Kapoor et al.   LANCET NEUROLOGY

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells

(2016) Patrick J. Engelberts et al.   JOURNAL OF IMMUNOLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration

(2012) Barbara M. Davit et al.   AAPS Journal

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE